157 related articles for article (PubMed ID: 25960412)
1. Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
Urol Oncol; 2015 Jul; 33(7):331.e1-7. PubMed ID: 25960412
[TBL] [Abstract][Full Text] [Related]
2. SRD5A polymorphisms and biochemical failure after radical prostatectomy.
Audet-Walsh E; Bellemare J; Nadeau G; Lacombe L; Fradet Y; Fradet V; Huang SP; Bao BY; Douville P; Girard H; Guillemette C; Lévesque E
Eur Urol; 2011 Dec; 60(6):1226-34. PubMed ID: 21715084
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression.
Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Rodríguez-Gallego C; Rodríguez-Melcón JI; Lara PC
BMC Med Genet; 2014 Dec; 15():143. PubMed ID: 25540025
[TBL] [Abstract][Full Text] [Related]
4. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
Setlur SR; Chen CX; Hossain RR; Ha JS; Van Doren VE; Stenzel B; Steiner E; Oldridge D; Kitabayashi N; Banerjee S; Chen JY; Schäfer G; Horninger W; Lee C; Rubin MA; Klocker H; Demichelis F
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):229-39. PubMed ID: 20056642
[TBL] [Abstract][Full Text] [Related]
6. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Choi SY; Kim HJ; Cheong HS; Myung SC
Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
8. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
[No Abstract] [Full Text] [Related]
9. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
10. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
11. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
Audet-Walsh É; Yee T; Tam IS; Giguère V
Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
[TBL] [Abstract][Full Text] [Related]
12. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
[TBL] [Abstract][Full Text] [Related]
13. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
Price DK; Chau CH; Till C; Goodman PJ; Leach RJ; Johnson-Pais TL; Hsing AW; Hoque A; Parnes HL; Schenk JM; Tangen CM; Thompson IM; Reichardt JK; Figg WD
Cancer; 2016 Aug; 122(15):2332-40. PubMed ID: 27164191
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in the androgen metabolism pathway and risk of prostate cancer in low incidence Malaysian ethnic groups.
Poniah P; Mohamed Z; Apalasamy YD; Mohd Zain S; Kuppusamy S; Razack AH
Int J Clin Exp Med; 2015; 8(10):19232-40. PubMed ID: 26770559
[TBL] [Abstract][Full Text] [Related]
15. Associations of SRD5A1 gene variants and testosterone with dysglycemia: Henan Rural Cohort study.
Liu X; Wei D; Jiang J; Liu X; Tu R; Luo Z; Wang Y; Dong X; Qiao D; Shen F; Li R; Wang Y; Jin Y; Yu S; Huo W; Li L; Li W; Jing T; Wang C; Mao Z
Nutr Metab Cardiovasc Dis; 2020 Apr; 30(4):599-607. PubMed ID: 31870594
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
17. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
19. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
20. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
